Stockholm, April 15, 2025 - The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

The European Commission has approved the antibody lecanemab to treat Alzheimer's, the first time it has authorized a therapy which targets the underlying disease processes, rather than just the ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

The European Commission has for the first time approved an Alzheimer's therapy that targets the underlying disease processes. Lecanemab, an antibody, is for early-stage treatment and is the first drug ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Roche’s Brainshuttle tech shows promise in Alzheimer’s treatment, enabling better drug delivery to the brain in trials.

Sporting a bright yellow "End Alz" jersey, a white baseball cap and blue-green neck warmer, Ralph Carmona bounced up and down on his wiry legs, warming up for a run on a sunny but brisk morning in ...

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...